Endometrial Carcinoma Clinical Trial
Official title:
Longitudinal Changes in Women's Pelvic Health and Sexual Function After Pelvic Radiation
This study investigates changes in physical measures of pelvic health and patient-reported outcomes of sexual function, intimate relationship, and quality of life over time in women undergoing radiation therapy for pelvic cancer. Evaluating vaginal changes prior to and after a course of radiation and collecting patient reported outcomes of sexual function, partner communication, and intimacy may help researchers may help researchers better understand physical changes and symptoms over time.
PRIMARY OBJECTIVES: I. To evaluate changes in objective physical exam findings from baseline to the end of radiation and through two years follow-up for women with pelvic cancer. II. To examine changes in sexual, relational and quality of life outcomes from baseline to the end of radiation and through one year follow-up for women with pelvic cancer using the patient reported outcome measures. III. To compare physical exam and patient-reported outcome trajectories over time. OUTLINE: Patients undergo standard of care pelvic exam at baseline and 1, 3, 6, 12, and 24 month follow ups. Patients also complete patient reported outcome measures at baseline and 1, 3, 6, 12, 18, and 12 month follow ups. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05059444 -
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
|
||
Recruiting |
NCT05036681 -
A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma
|
Phase 2 | |
Completed |
NCT00756847 -
Safety Study of XL147 (SAR245408), in Combination With Paclitaxel and Carboplatin in Adults With Solid Tumors
|
Phase 1 | |
Completed |
NCT00729586 -
Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer
|
Phase 2 | |
Completed |
NCT02983279 -
Caloric Restriction Before Surgery in Treating Patients With Endometrial, Prostate, or Breast Cancer
|
N/A | |
Completed |
NCT02017353 -
Effect of Curcumin Addition to Standard Treatment on Tumour-induced Inflammation in Endometrial Carcinoma
|
Phase 2 | |
Completed |
NCT00997373 -
Letrozole as a Treatment of Endometrial Cancer
|
N/A | |
Recruiting |
NCT04851119 -
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04576104 -
Megestrol Acetate Compared With Megestrol Acetate and Metformin to Prevent Endometrial Cancer
|
Phase 2 | |
Not yet recruiting |
NCT06102252 -
Combination Chemotherapy of Paclitaxel and Carboplatin With or Without Anthracycline as an Adjuvant Treatment in Endometrial Carcinoma
|
N/A | |
Active, not recruiting |
NCT02598219 -
Evaluation of Sentinel Node Policy in Early Stage Endometrial Carcinomas at Intermediate and High Risk of Recurrence.
|
Phase 3 | |
Recruiting |
NCT04159155 -
A Study of Various Treatments in Serous or p53 Abnormal Endometrial Cancer
|
Phase 2/Phase 3 | |
Recruiting |
NCT05139368 -
Hypofractionated Radiotherapy for the Treatment of Cervical or Endometrial Cancer
|
N/A | |
Recruiting |
NCT02611024 -
Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03849469 -
A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors
|
Phase 1 | |
Suspended |
NCT06253494 -
Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03917381 -
GEN1046 Safety Trial in Patients With Malignant Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03372720 -
Fractional CO2 Laser Therapy in Minimizing Genitourinary Syndrome of Menopause in Gynecological Cancer Survivors
|
N/A | |
Recruiting |
NCT06413992 -
Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer
|
Phase 2 | |
Recruiting |
NCT05316467 -
Weight Management Plus Megestrol Acetate in Early-stage Endometrioid Carcinoma
|
Phase 2/Phase 3 |